Aptevo Therapeutics APVO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.14 (-5.22%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aptevo Therapeutics (APVO)
    Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $2.54

    • Market Cap

      $3.70 Million

    • Price-Earnings Ratio

      0.00

    • Total Outstanding Shares

      1.46 Million Shares

    • Total Employees

      37

    • Dividend

      No dividend

    • IPO Date

      July 20, 2016

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      2401 4th ave., Seattle, WA, 98121

    • Homepage

      https://www.aptevotherapeutics.com

    Historical Stock Splits

    If you bought 22,792 shares of APVO before March 27, 2020, you'd have 1 share today.
    Execution DateSplit Amount
    December 4, 20241-for-37 (Reverse Split)
    March 6, 20241-for-44 (Reverse Split)
    March 27, 20201-for-14 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$11.92 Million
    Net Cash Flow, Continuing$0
    Net Cash Flow From Financing Activities, Continuing$11.92 Million
    Net Cash Flow From Investing Activities$11.36 Million
    Net Cash Flow From Operating Activities$-23.28 Million
    Net Cash Flow$0

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Basic Average Shares$26.79 Million
    Preferred Stock Dividends And Other Adjustments$0
    Research and Development$14.09 Million
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Income/Loss From Continuing Operations Before Tax$-24.01 Million
    Net Income/Loss Available To Common Stockholders, Basic$-23.72 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-23.72 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$-23.72 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Noncurrent Liabilities$4.84 Million
    Equity Attributable To Noncontrolling Interest$0
    Equity$4.42 Million
    Equity Attributable To Parent$4.42 Million
    Other Non-current Assets$4.52 Million
    Wages$922,000

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about APVO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.